Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Spatial predictors of immunotherapy response in triple-negative breast cancer.
Wang XQ, Danenberg E, Huang CS, Egle D, Callari M, Bermejo B, Dugo M, Zamagni C, Thill M, Anton A, Zambelli S, Russo S, Ciruelos EM, Greil R, Győrffy B, Semiglazov V, Colleoni M, Kelly CM, Mariani G, Del Mastro L, Biasi O, Seitz RS, Valagussa P, Viale G, Gianni L, Bianchini G, Ali HR. Wang XQ, et al. Among authors: seitz rs. Nature. 2023 Sep;621(7980):868-876. doi: 10.1038/s41586-023-06498-3. Epub 2023 Sep 6. Nature. 2023. PMID: 37674077 Free PMC article.
Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic Chemotherapy.
Masuda H, Harano K, Miura S, Wang Y, Hirota Y, Harada O, Jolly MK, Matsunaga Y, Lim B, Wood AL, Parinyanitikul N, Jin Lee H, Gong G, George JT, Levine H, Lee J, Wang X, Lucci A, Rao A, Schweitzer BL, Lawrence OR, Seitz RS, Morris SW, Hout DR, Nakamura S, Krishnamurthy S, Ueno NT. Masuda H, et al. Among authors: seitz rs. JCO Precis Oncol. 2022 Mar;6:e2000368. doi: 10.1200/PO.20.00368. JCO Precis Oncol. 2022. PMID: 35294223 Free PMC article.
The 27-gene IO score is associated with efficacy of PD-1/L1 inhibitors independent of FGFR expression in a real-world metastatic urothelial carcinoma cohort.
Nielsen TJ, Varga MG, Cronister CT, Ring BZ, Seitz RS, Ross DT, Schweitzer BL, McGregor K. Nielsen TJ, et al. Among authors: seitz rs. Cancer Immunol Immunother. 2023 Jul;72(7):2075-2086. doi: 10.1007/s00262-023-03401-x. Epub 2023 Feb 19. Cancer Immunol Immunother. 2023. PMID: 36806983 Free PMC article.
Identification of triple-negative breast cancer cell lines classified under the same molecular subtype using different molecular characterization techniques: Implications for translational research.
Espinosa Fernandez JR, Eckhardt BL, Lee J, Lim B, Pearson T, Seitz RS, Hout DR, Schweitzer BL, Nielsen TJ, Lawrence OR, Wang Y, Rao A, Ueno NT. Espinosa Fernandez JR, et al. Among authors: seitz rs. PLoS One. 2020 Apr 30;15(4):e0231953. doi: 10.1371/journal.pone.0231953. eCollection 2020. PLoS One. 2020. PMID: 32353087 Free PMC article.
An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer.
Antoniotti C, Boccaccino A, Seitz R, Giordano M, Catteau A, Rossini D, Pietrantonio F, Salvatore L, McGregor K, Bergamo F, Conca V, Leonetti S, Morano F, Papiani G, Tamburini E, Bensi M, Murgioni S, Ross DT, Passardi A, Boquet I, Nielsen TJ, Galon J, Varga MG, Schweitzer BL, Cremolini C. Antoniotti C, et al. Clin Cancer Res. 2023 Jun 13;29(12):2291-2298. doi: 10.1158/1078-0432.CCR-22-3878. Clin Cancer Res. 2023. PMID: 37022350 Clinical Trial.
Rates of immune cell infiltration in patients with triple-negative breast cancer by molecular subtype.
Harano K, Wang Y, Lim B, Seitz RS, Morris SW, Bailey DB, Hout DR, Skelton RL, Ring BZ, Masuda H, Rao AUK, Laere SV, Bertucci F, Woodward WA, Reuben JM, Krishnamurthy S, Ueno NT. Harano K, et al. Among authors: seitz rs. PLoS One. 2018 Oct 12;13(10):e0204513. doi: 10.1371/journal.pone.0204513. eCollection 2018. PLoS One. 2018. PMID: 30312311 Free PMC article.
38 results